10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial.

Victor Maduabuchi OguomaNicole WilsonKim MulhollandMathuram SantoshamPaul TorzilloPeter McIntyreHeidi Smith-VaughanAnne BallochMark ChatfieldDeborah LehmannMichael J BinksAnne ChangJonathan CarapetisVicki KrauseRoss AndrewsTom SnellingPaul LicciardiPeter MorrisAmanda Jane Leach

Published in: BMJ open (2020)

NCT01735084.

Keyphrases

cancer therapy
young adults
protein protein
amino acid
binding protein
drug delivery